AIPher
Tsinghua AIR spin-out building DrugCLIP virtual screening and the PharmAgents decision agent, used to co-develop drug programs with pharma partners; lead ADHD program is pre-PCC.
Money and evidence
Latest round, Angel, 2026-09-03: the record then held 1 research entry, highest level 4. The first research entry is dated 2026-01-08; the highest level so far is 4 (Tested in the physical world).
Rounds and research, on one timeline
- 2026-09-03AngelRound
on the order of 100 million yuan
For: DrugCLIP and PharmAgents R&D, wet-dry lab loop, own and partnered pipelines
Models and platformWet labCommercial roll-out
36Kr first report with Bowen Gao on record; the company's release via PEdaily and adviser Lighthouse Capital confirm it. Company founded July 2026.
Lead · Xianghe CapitalXinglian Capitalan unnamed industry fund
By this date the record held 1 research entry, highest level 4
- 2026-01-08Research
Level 4 · Tested in the physical world
Tsinghua's DrugCLIP screens about 10,000 human proteins against 500 million compounds, and its picks hit in the lab at 15% and 17.5% on two targets
Docking is too slow to run against every human protein; this makes it cheap, and the precomputed results are open as GenomeScreenDB. The hits were measured in the lab, but by the authors themselves, and the hit rates come without a figure for how potent the hits are. It is the method behind AIPher, the Tsinghua AIR spin-out that raised an angel round in September.
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
Its investors also backed
Other companies on this page whose rounds name the same investor.
- Xianghe CapitalHelixon (Earendil Labs)
- Xinglian CapitalBioGeometry